

50562-P001US sequence listing revised FINAL\_ST25.txt  
SEQUENCE LISTING

<110> The Johns Hopkins University  
Denmead, Samuel  
Isaacs, John  
Lilja, Hans

<120> Activation of Peptide Prodrugs by hK2

<130> 50562-P001US

<140> 10/535,351  
<141> 2006-04-14

<150> PCT/US03/36880  
<151> 2003-11-18

<150> 60/427,309  
<151> 2002-11-18

<160> 54

<170> PatentIn version 3.5

<210> 1  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 1

Gly Lys Ala Arg Ala Phe  
1 5

<210> 2  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 2

Gly Lys Ala Val Arg Gln  
1 5

<210> 3  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 3

Gly Lys Ala Tyr Phe Met

<210> 4  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 4

Gly Lys Ala Glu Lys Val  
1 5

<210> 5  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 5

Gly Lys Ala Phe Arg Lys  
1 5

<210> 6  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 6

Gly Lys Ala Lys Pro Arg  
1 5

<210> 7  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 7

Gly Lys Ala Ala Tyr Tyr  
1 5

<210> 8  
<211> 6  
<212> PRT  
<213> artificial sequence

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>

<223> synthetic peptide

<400> 8

Gly Lys Ala Trp Tyr His  
1 5

<210> 9

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 9

Gly Lys Ala Phe Arg Arg  
1 5

<210> 10

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 10

Gly Lys Ala Ile Gln Arg  
1 5

<210> 11

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 11

Gly Lys Ala Met Arg Gln  
1 5

<210> 12

<211> 6

<212> PRT

<213> artificial sequence

<220>

<223> synthetic peptide

<400> 12

Gly Lys Ala Ala Leu Met

<210> 13  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 13

Gly Lys Ala Gln Gly Phe  
1 5

<210> 14  
<211> 6  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 14

Gly Lys Ala Asn Met Asn  
1 5

<210> 15  
<211> 5  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 15

Leu Ile Gln Ser Arg  
1 5

<210> 16  
<211> 5  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 16

Asp Asp Asp Asp Lys  
1 5

<210> 17  
<211> 6  
<212> PRT  
<213> artificial sequence

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>  
<223> synthetic peptide

<220>  
<221> misc\_feature  
<222> (4)..(6)  
<223> X is any amino acid

<400> 17

Gly Lys Ala Xaa Xaa Xaa  
1 5

<210> 18  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is acetylated 3-nitrotyrosine

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 18

Xaa Gly Lys Ala Phe Arg Arg Leu Gly Xaa  
1 5 10

<210> 19  
<211> 8  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 19

Gly Ser Lys Gly His Phe Arg Leu  
1 5

<210> 20  
<211> 8  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

50562-P001US sequence listing revised FINAL\_ST25.txt

<400> 20

Gly Ser Lys Gly His Phe His Leu  
1 5

<210> 21  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 21

Xaa Gly Lys Ala Phe Arg Arg Leu Gly Xaa  
1 5 10

<210> 22  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 22

Gly Lys Ala Arg Ala Phe Leu  
1 5

<210> 23  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 23

Gly Lys Ala Val Arg Gln Leu  
1 5

<210> 24  
<211> 7  
<212> PRT  
<213> artificial sequence

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>  
<223> synthetic peptide  
<400> 24  
Gly Lys Ala Tyr Phe Met Leu  
1 5

<210> 25  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide  
<400> 25  
Gly Lys Ala Glu Lys Val Leu  
1 5

<210> 26  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide  
<400> 26  
Gly Lys Ala Phe Arg Lys Leu  
1 5

<210> 27  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide  
<400> 27  
Gly Lys Ala Lys Pro Arg Leu  
1 5

<210> 28  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide  
<400> 28  
Gly Lys Ala Ala Tyr Tyr Leu

<210> 29  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 29

Gly Lys Ala Trp Tyr His Leu  
1 5

<210> 30  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 30

Gly Lys Ala Phe Arg Arg Leu  
1 5

<210> 31  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 31

Gly Lys Ala Ile Gln Arg Leu  
1 5

<210> 32  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<400> 32

Gly Lys Ala Met Arg Gln Leu  
1 5

<210> 33  
<211> 7  
<212> PRT  
<213> artificial sequence

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>  
<223> synthetic peptide

<400> 33

Gly Lys Ala Ala Leu Met Leu  
1 5

<210> 34  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 34

Gly Lys Ala Gln Gly Phe Leu  
1 5

<210> 35  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<400> 35

Gly Lys Ala Asn Met Asn Leu  
1 5

<210> 36  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>

<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 36

50562-P001US sequence listing revised FINAL\_ST25.txt

Xaa Gly Lys Ala Arg Ala Phe Xaa Phe Xaa  
1 5 10

<210> 37  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 37

Xaa Gly Lys Ala Lys Pro Arg Xaa Phe Xaa  
1 5 10

<210> 38  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 38

Xaa Gly Lys Ala Phe Arg Arg Xaa Phe Xaa  
1 5 10

50562-P001US sequence listing revised FINAL\_ST25.txt

<210> 39  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted Lysine (Lys-Abz)

<400> 39

Xaa Gly Lys Ala Met Arg Gln Xaa Phe Xaa  
1 5 10

<210> 40  
<211> 12  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (12)..(12)  
<223> X is 2-aminobenzoic acid substituted lysine (Lys-Abz)

<400> 40

Xaa Gly Ser Lys Gly His Phe Lys Leu Xaa Phe Xaa  
1 5 10

<210> 41

50562-P001US sequence listing revised FINAL\_ST25.txt

<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> X is leucine functionalized at the C-terminal end with 12ADT  
(L12ADT).

<400> 41

Gly Lys Ala Phe Arg Arg Xaa  
1 5

<210> 42  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 42

Xaa Gly Lys Ala Phe Arg Arg Xaa Gly Xaa  
1 5 10

<210> 43  
<211> 8  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION

<400> 43

Gly Lys Ala Phe Arg Arg Leu Gly  
1 5

<210> 44  
<211> 7  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> X is leucine C-terminal functionalized with 12ADT (L12ADT)

<400> 44

Gly Lys Ala Phe Arg Arg Xaa  
1 5

<210> 45  
<211> 11  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 45

Xaa Gly Ser Lys Gly His Phe Lys Leu Xaa Xaa  
1 5 10

<210> 46

50562-P001US sequence listing revised FINAL\_ST25.txt

<211> 11  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 46

Xaa Gly Ser Lys Gly Pro Phe Lys Leu Xaa Xaa  
1 5 10

<210> 47  
<211> 11  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 47

Xaa Gly Ser Lys Gly His Phe His Leu Xaa Xaa  
1 5 10

<210> 48  
<211> 10  
<212> PRT  
<213> artificial sequence

50562-P001US sequence listing revised FINAL\_ST25.txt

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MISC\_FEATURE  
<222> (5)..(7)  
<223> X is any L-amino acid except cysteine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz)

<400> 48

Xaa Gly Lys Ala Xaa Xaa Xaa Xaa Phe Xaa  
1 5 10

<210> 49  
<211> 10  
<212> PRT  
<213> artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MISC\_FEATURE  
<222> (5)..(7)  
<223> X is any L-amino acid except cysteine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid substituted lysine bound to a solid phase PEGA support

<400> 49

50562-P001US sequence listing revised FINAL\_ST25.txt  
Xaa Gly Lys Ala Xaa Xaa Xaa Phe Xaa  
1 5 10

<210> 50  
<211> 6  
<212> PRT  
<213> artificial sequence  
  
<220>  
<223> synthetic peptide  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is any natural amino acid except cysteine protected with an Fmoc group  
  
<220>  
<221> MISC\_FEATURE  
<222> (2)..(3)  
<223> X is any natural amino acid except cysteine  
  
<220>  
<221> MOD\_RES  
<222> (4)..(4)  
<223> Dpr  
  
<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> X is 2-aminobenzoic acid-substituted lysine (Lys-Abz) bound to a PEGA solid support  
  
<400> 50  
  
Xaa Xaa Xaa Xaa Phe Xaa  
1 5

<210> 51  
<211> 7  
<212> PRT  
<213> artificial sequence  
  
<220>  
<223> synthetic peptide  
  
<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION  
  
<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> X is lysine protected with a side-chain ivdde protecting group  
  
<400> 51

Gly Xaa Ala Phe Arg Arg Leu

1

50562-P001US sequence listing revised FINAL\_ST25.txt  
5

<210> 52  
<211> 8  
<212> PRT  
<213> artificial sequence  
<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> X is 2-aminobenzoic acid substituted lysine (Lys-Abz) attached to  
a PEGA solid support

<400> 52

Xaa Gly Lys Ala Phe Arg Leu Xaa  
1 5

<210> 53  
<211> 10  
<212> PRT  
<213> artificial sequence  
<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> X is 3-nitrotyrosine

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> Dpr

<220>  
<221> MISC\_FEATURE  
<222> (10)..(10)  
<223> X is 2-aminobenzoic acid-substituted lysine attached to a PEGA  
solid phase support

<400> 53

Xaa Gly Lys Ala Phe Arg Leu Xaa Phe Xaa  
1 5 10

<210> 54  
<211> 8  
<212> PRT

50562-p001us sequence listing revised FINAL\_ST25.txt

<213> artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> X is glycine N-terminal bound to a 2-aminobenzoic acid group  
(Abz)

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> X is 3-nitrotyrosine

<400> 54

Xaa Lys Ala Phe Arg Arg Leu Xaa  
1                       5